Ionis Pharmaceuticals (IONS) Revenue & Revenue Breakdown
Ionis Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$787.65M
Latest Revenue (Q)
$225.25M
Main Segment (Y)
Research and Development Revenue
Ionis Pharmaceuticals Revenue by Period
Ionis Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $787.65M | 34.18% |
2022-12-31 | $587.00M | -27.53% |
2021-12-31 | $810.00M | 11.11% |
2020-12-31 | $729.00M | -35.08% |
2019-12-31 | $1.12B | 87.27% |
2018-12-31 | $599.67M | 18.12% |
2017-12-31 | $507.67M | 46.46% |
2016-12-31 | $346.62M | 22.18% |
2015-12-31 | $283.70M | 32.47% |
2014-12-31 | $214.16M | 45.41% |
2013-12-31 | $147.28M | 44.33% |
2012-12-31 | $102.05M | 2.99% |
2011-12-31 | $99.09M | -8.65% |
2010-12-31 | $108.47M | -10.80% |
2009-12-31 | $121.60M | 13.44% |
2008-12-31 | $107.19M | 53.96% |
2007-12-31 | $69.62M | 183.80% |
2006-12-31 | $24.53M | -38.87% |
2005-12-31 | $40.13M | -5.84% |
2004-12-31 | $42.62M | -14.73% |
2003-12-31 | $49.99M | -37.65% |
2002-12-31 | $80.18M | 50.51% |
2001-12-31 | $53.27M | 43.00% |
2000-12-31 | $37.26M | 9.90% |
1999-12-31 | $33.90M | -13.52% |
1998-12-31 | $39.20M | 20.62% |
1997-12-31 | $32.50M | 43.81% |
1996-12-31 | $22.60M | 73.85% |
1995-12-31 | $13.00M | 28.71% |
1994-12-31 | $10.10M | -16.53% |
1993-12-31 | $12.10M | - |
Ionis Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $225.25M | 88.50% |
2024-03-31 | $119.50M | -63.18% |
2023-12-31 | $324.50M | 125.35% |
2023-09-30 | $144.00M | -23.40% |
2023-06-30 | $188.00M | 43.51% |
2023-03-31 | $131.00M | -13.82% |
2022-12-31 | $152.00M | -4.86% |
2022-09-30 | $159.77M | 19.42% |
2022-06-30 | $133.79M | -5.73% |
2022-03-31 | $141.92M | -67.75% |
2021-12-31 | $440.00M | 230.60% |
2021-09-30 | $133.09M | 5.84% |
2021-06-30 | $125.75M | 12.67% |
2021-03-31 | $111.61M | -61.51% |
2020-12-31 | $290.00M | 81.16% |
2020-09-30 | $160.08M | 9.99% |
2020-06-30 | $145.54M | 9.13% |
2020-03-31 | $133.37M | -73.00% |
2019-12-31 | $494.00M | 194.24% |
2019-09-30 | $167.89M | 2.37% |
2019-06-30 | $164.00M | -44.82% |
2019-03-31 | $297.21M | 54.71% |
2018-12-31 | $192.11M | 32.13% |
2018-09-30 | $145.40M | 23.48% |
2018-06-30 | $117.75M | -18.47% |
2018-03-31 | $144.42M | -16.18% |
2017-12-31 | $172.30M | 42.50% |
2017-09-30 | $120.91M | 16.09% |
2017-06-30 | $104.15M | -5.58% |
2017-03-31 | $110.30M | -31.21% |
2016-12-31 | $160.35M | 44.55% |
2016-09-30 | $110.93M | 188.35% |
2016-06-30 | $38.47M | 4.33% |
2016-03-31 | $36.87M | -28.50% |
2015-12-31 | $51.57M | 4.99% |
2015-09-30 | $49.12M | -59.21% |
2015-06-30 | $120.43M | 92.43% |
2015-03-31 | $62.58M | -26.25% |
2014-12-31 | $84.86M | 92.59% |
2014-09-30 | $44.06M | -22.80% |
2014-06-30 | $57.08M | 102.68% |
2014-03-31 | $28.16M | -33.35% |
2013-12-31 | $42.25M | 79.14% |
2013-09-30 | $23.59M | -38.08% |
2013-06-30 | $38.09M | -12.15% |
2013-03-31 | $43.36M | 118.19% |
2012-12-31 | $19.87M | 71.30% |
2012-09-30 | $11.60M | -75.49% |
2012-06-30 | $47.34M | 103.74% |
2012-03-31 | $23.23M | -28.29% |
2011-12-31 | $32.40M | 56.44% |
2011-09-30 | $20.71M | -16.56% |
2011-06-30 | $24.82M | 17.38% |
2011-03-31 | $21.15M | -19.96% |
2010-12-31 | $26.42M | -7.70% |
2010-09-30 | $28.62M | 21.79% |
2010-06-30 | $23.50M | -21.46% |
2010-03-31 | $29.93M | -7.24% |
2009-12-31 | $32.26M | 20.51% |
2009-09-30 | $26.77M | -13.62% |
2009-06-30 | $30.99M | -1.85% |
2009-03-31 | $31.58M | 52.83% |
2008-12-31 | $20.66M | -35.87% |
2008-09-30 | $32.22M | -2.26% |
2008-06-30 | $32.96M | 54.36% |
2008-03-31 | $21.35M | -13.64% |
2007-12-31 | $24.73M | - |
Ionis Pharmaceuticals Revenue Breakdown
Ionis Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
SPINRAZA Royalties | $240.38M | $292.99M | - | - | - |
Licensing and Other Royalties | $33.30M | $30.99M | $19.12M | $8.12M | $17.20M |
Other Commercial | $68.21M | - | - | - | - |
Product | $34.91M | $30.05M | $70.00M | $42.25M | - |
Research and Development Revenue | $479.06M | $284.01M | - | - | - |
Commercial | $308.59M | $303.36M | $342.39M | $364.70M | $352.45M |
Collaborative Agreement Revenue | $352.66M | $207.22M | - | - | - |
Spinraza Royalties | - | $242.31M | $267.78M | $286.58M | - |
Eplontersen Joint Development Revenue | - | $76.79M | - | - | - |
Research and Development Revenue Under Collaborative Agreements | - | - | $468.06M | $364.56M | $770.15M |
TEGSEDI and WAYLIVRA | - | - | $55.50M | - | - |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 |
---|---|---|---|---|---|
Other Commercial | $13.15M | $11.51M | $34.50M | $16.83M | $16.89M |
Licensing and Other Royalties | $4.23M | $3.32M | $13.71M | $8.54M | - |
Commercial | $75.73M | $72.04M | $78.84M | $84.08M | $77.90M |
SPINRAZA Royalties | $57.21M | $56.74M | $112.11M | $67.25M | $61.01M |
Research and Development Revenue | $58.08M | $153.21M | $245.66M | $60.13M | $110.51M |
Product | $8.92M | $8.19M | $20.15M | $8.29M | - |
Collaborative Agreement Revenue | $44.88M | $141.52M | $179.14M | $44.17M | $91.01M |
Eplontersen Joint Development Revenue | - | - | - | $15.96M | $19.50M |
Latest
Ionis Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
INCY | Incyte | $3.70B | $962.99M |
BMRN | BioMarin Pharmaceutical | $2.42B | $733.87B |
EXEL | Exelixis | $1.83B | $478.06M |
ALNY | Alnylam Pharmaceuticals | $1.83B | $420.15M |
SRPT | Sarepta Therapeutics | $1.24B | $362.93M |
PTCT | PTC Therapeutics | $937.82M | $135.42M |
HALO | Halozyme Therapeutics | $829.25M | $290.08M |
IONS | Ionis Pharmaceuticals | $787.65M | $225.25M |
APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
ARWR | Arrowhead Pharmaceuticals | $240.74M | - |
KRYS | Krystal Biotech | $50.70M | $83.84M |
IOVA | Iovance Biotherapeutics | $1.19M | $58.55M |
VKTX | Viking Therapeutics | - | - |
MDGL | Madrigal Pharmaceuticals | - | $62.17M |
TERN | Terns Pharmaceuticals | - | - |
AKRO | Akero Therapeutics | - | - |